Korea’s Green Cross Anticipates Growth In Upcoming Flu Season
This article was originally published in PharmAsia News
The upcoming flu season should provide more momentum to Korea’s leading vaccine company, which saw marginal year-on-year growth in the second quarter.
You may also be interested in...
SEOUL - South Korean vaccine producer Green Cross said it signed a three-year $480 million memorandum of understanding with ASD Healthcare of the U.S. to export intravenous immunoglobulin and hemophilia type A treatment GreenGene-F to the U.S, which would be the country's largest-ever agreement for finished drugs
Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline
SEOUL - Of the many local Korean pharmaceutical players, vaccine producer Green Cross was the biggest beneficiary of the A/H1N1 flu pandemic last year as increased demand for its vaccines triggered a remarkable upgrade in its rankings to the second-largest from its previous long-time position of No. 5
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.